Overview

Efficacy, Safety, and PK of Ascending Dosages of Moxidectin Versus Ivermectin Against Strongyloides Stercoralis

Status:
Enrolling by invitation

Trial end date:
2021-12-01

Target enrollment:

Participant gender:

Summary

This study is a phase 2, blinded and randomized clinical trial. The phase 2a trial is single blinded and conducted in Lao, while the phase 2b trial is double-blinded and conducted in Lao and Cambodia. The study aims at providing evidence on effective doses and safety of moxidectin in adults against infection with S. stercoralis in Laos (trial 2a) and efficacy and safety of moxidectin compared to ivermectin in adults against infection with S. stercoralis in Laos and Cambodia (trial 2b). The efficacy of the treatment will be assessed by collecting three stool samples once pre-treatment and once 21 days post-treatment. The stool samples will be analyzed by a quantitative Baermann assay.

Phase:

Phase 2

Details

Lead Sponsor:

Jennifer Keiser

Collaborators:

National Centre for Parasitology, Entomology and Malaria Control, Cambodia
National Institute of Public Health, Vientiane, Laos

Treatments:

Ivermectin
Milbemycin
Moxidectin